Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-label Study of Subcutaneous CPG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer

NCT00824733 is registered in ClinicalTrials.gov with Bhuvaneswari Ramaswamy as lead sponsor.

NCT NCT00824733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00824733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-label Study of Subcutaneous CPG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer
Lead sponsor
Bhuvaneswari Ramaswamy
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2009
Completion date
April 30, 2014
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer